Here we report the direct effects of alendronate on the proliferation and osteogenic differentiation of the MG-63 osteoblast-like cell line. Cell proliferation was determined with the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, osteogenic differentiation was evaluated with an alkaline phosphatase bioassay and by analysis of gene expression by reverse transcription-polymerase chain reaction, and the extent of calcium deposition was measured using Alizarin Red S staining. Alendronate significantly increased cell numbers over control values, with the greatest effect at 10 −8 M. Alkaline phosphatase activity and gene expression of bone morphogenetic protein 2, type I collagen and osteocalcin were increased after alendronate treatment. Alendronate also stimulated calcium deposition. We conclude that alendronate, apart from inhibiting osteoclastic bone resorption, is also a promoter of osteoblast proliferation and maturation.
Introduction
Bisphosphonates are the clinically most important class of antiresorptive agents available to treat diseases characterized by osteoclast-mediated bone resorption, such as post-menopausal osteoporosis, Paget's disease and tumour-associated bone diseases. 1, 2 They are synthetic, metabolically stable analogues of inorganic pyrophosphate in which the P-O-P bond has been replaced with a non-hydrolysable P-C-P bond. The diphosphate configuration of both P-O-P and P-C-P contributes to a three-dimensional structure capable of binding divalent ions, such as Ca 2+ , and is the basis for the bone-targeting property of these compounds. 3, 4 Bisphosphonates have been shown to have direct effects on osteoclasts. They are traditionally divided into nitrogencontaining (N) and non-nitrogen-containing (non-N) categories. The N-bisphosphonates Y Xiong, HJ Yang, J Feng et al. Alendronate and MG-63 cells impede the mevalonate pathway of cholesterol synthesis by competitively inhibiting the binding of isopentenyl pyrophosphate to farnesyl diphosphate synthase, resulting in decreased amounts of farnesyl pyrophosphate, an essential donor of prenyl moieties. This decrease causes a lack of prenylation of the small GTPases, which is essential for osteoclast activity and survival and, ultimately, results in inhibition of osteoclast formation and function. 5 -7 Non-N-bisphosphonates can be metabolically incorporated into non-hydrolysable analogues of ATP that can inhibit ATP-dependent intracellular enzymes, thus leading to cell death. 1, 8 There is increasing evidence that bisphosphonates, in addition to their direct effects on osteoclasts, also interact with osteoblasts by modulating the expression of osteoclastogenic factors synthesized by osteoblasts. 9 -13 Giuliani et al. 9 reported that alendronate and etidronate inhibited cytokine-induced interleukin 6 secretion by human osteoblastic osteosarcoma cells (cell line MG-63) in a dose-dependent manner. A study by Vitté et al. 10 showed that the bisphosphonates, ibandronate and alendronate, at a concentration of 10 −7 M induced osteoblasts to synthesize an osteoclast inhibitor that was heat-and proteinase-labile and had a molecular mass of 1 -10 kDa. Pan et al. 13 demonstrated that zolendronate decreased transmembrane receptor activator of nuclear factor κB ligand (RANKL) expression on osteoblasts by increasing the activity of a RANKL sheddase, TACE (tumour necrosis factor [TNF]-α converting enzyme). Mundy et al. 14 reported that statins, a class of drugs that is clinically used to suppress cholesterol synthesis, act on the mevalonate pathway by blocking the more upstream 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, thereby increasing bone formation in vitro and in vivo. The mechanism by which bisphosphonates achieve their clinical efficacy has been reported to be, at least in part, by inhibition of the mevalonate pathway. 15 New studies indicate that bisphosphonates may also have anabolic effects on osteoblasts, however the results have not been consistent, differing according to the bisphosphonate and the model system used. 16 -20 Alendronate sodium, one of the most commonly used antiresorptive pharmacological agents, is a nitrogen-containing bisphosphonate and, unlike other bisphosphonates (such as etidronate and pamidronate), it does not impair mineralization. 21 The effects of alendronate on osteoclasts and its mechanism of action have been well described, 7 although the mechanism of action remains somewhat unclear. The objective of the present study was to investigate the effects of alendronate on the proliferation and osteogenic differentiation of the osteoblast-like line, MG-63. 
Materials and methods

MATERIALS
CELL CULTURE
The MG-63 osteoblast-like cells were cultured at a density of 2 × 10 5 cells/cm 2 in H-DMEM medium supplemented with 10% fetal bovine serum, L-glutamine (2 mM), 10 mM β-glycerophosphate and 50 ng/ml L-ascorbic at 37°C under 5% CO 2 and 95% humidity. Every 3 or 4 days, when cells had grown to 80% confluence, they were isolated from culture dishes by trypsinization and washed with 10 mM phosphate-buffered saline (PBS), pH 7.2.
After the second passage, the MG-63 cells were divided into five groups: group A was a negative control with medium alone; group B was a positive control, treated with 10 −8 M dexamethasone (dexamethasone promotes phenotypic markers of osteoblast differentiation and is a critical medium supplement for osteogenic differentiation. 22, 23 ) ; and groups C, D and E were experimental groups, treated with 10 −6 , 10 −8 and 10 −10 M alendronate, respectively. After 4 days of culture, MTT colourimetric assay, alkaline phosphatase assay, reverse transcription-polymerase chain reaction (RT-PCR) and Alizarin Red S staining, were performed as described below.
MTT COLOURIMETRIC ASSAY
The MG-63 cells were plated at a density of 2 × 10 4 cells/well in 96-well plates. After overnight incubation at 37°C, the cultures were continued for 48, 72 and 96 h in medium containing 10 −6 , 10 −8 or 10 −10 M alendronate. The MTT (20 µl, 5 mg/ml) was then added to each well and cultures continued for 4 h at 37°C. The medium was then aspirated and 150 µl of DMSO was added to each well. The supernatant was transferred to microplate wells and colourimetric changes were quantified in a microplate reader at a wavelength of 490 nm. The MTT colourimetric assay was performed in triplicate and repeated in five cultures. Data were expressed as the percentage optical density relative to the negative control of 100%.
ALKALINE PHOSPHATASE ASSAY
The MG-63 cells were plated at a density of 1.5 × 10 5 cells/well in six-well plates. After overnight incubation, alendronate was added at concentrations of 10 −6 , 10 −8 or 10 −10 M and cultures were continued for 48, 72 and 96 h. Triton X-100 (20 µl, 0.2%) was then added. The adherent cells were scraped off and collected in a microcentrifuge tube. The cell suspension was incubated at 4°C for 10 min with agitation, then centrifuged at 2500 g for 10 min. The supernatant was collected and 50 µl/well was added to a 96well plate. Alkaline phosphatase activity was assayed using the pNPP alkaline phosphatase assay kit. Colourimetric changes were measured spectrophotometrically at 405 nm and the amount of enzyme released by the cells was quantified by comparison with a standard curve. Alkaline phosphatase levels were normalized to cell number at the end of the experiment. The alkaline phosphatase assay was conducted in triplicate and repeated in five cultures.
RT-PCR METHOD
The MG-63 cells were plated at a density of 1.5 × 10 5 cells/well in six-well plates. After overnight incubation, alendronate was added at concentrations of 10 −6 , 10 −8 or 10 −10 M. After 96 h, total RNA was isolated from cells using TRIzol ® reagent. Lysates were extracted with chloroform and total RNA was precipitated with isopropanol. Total RNA was reverse-transcribed using random hexamers and reverse transcriptase. The first-strand cDNA product was subjected to PCR using oligonucleotide primer pairs for the genes for bone morphogenetic protein 2 (BMP2), type I collagen (COL1), osteocalcin (BGLAP) and a housekeeping gene, GAPDH (glyceraldehyde-3-phosphate dehydrogenase). Details of the primers and reaction conditions are listed in Table 1 . The RT-PCR reaction was repeated in three cultures. All RT-PCR products were analysed by electrophoresis in 1.5% agarose gel with 0.5 mg/ml ethidium bromide and visualized under ultraviolet.
ALIZARIN RED S STAINING
The MG-63 cells were plated at a density of 1.5 × 10 5 cells/well in six-well plates. After overnight incubation, alendronate was added at concentrations of 10 −6 , 10 −8 or 10 −10 M and cultures were continued for 7, 10 or 14 days. The degree of calcium deposition was determined in six-well plates using Alizarin Red S staining. Briefly, medium was aspirated from the wells and the cells were rinsed twice with 10 mM PBS, pH 7.2. The cells were then fixed with icecold 70% (v/v) ethanol for 1 h. After removal of ethanol, the cells were rinsed twice with deionized water and stained with Alizarin Red S in deionized water (adjusted to pH 4.2) for 10 min at room temperature. The Alizarin Red S solution was removed by aspiration and the cells were rinsed five times with deionized water. The water was removed by aspiration and the cells were incubated in PBS for 15 min at room temperature on an orbital rotator. The PBS was removed and the cells were rinsed once with fresh PBS. The cells were then destained for 15 min with 10% (w/v) cetylpyridinium chloride in 10 mM sodium phosphate (pH 7.0). The extracted stain was then transferred to a 96-well plate and absorbance at 562 nm was measured using a SpectraMax ® 340 plate reader/ spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). 
STATISTICAL ANALYSIS
Results for each culture are presented as the mean ± SE percentages or decimal fractions relative to the negative controls. The data were subjected to one-way analysis of variance and statistical significance was P < 0.05.
Results
MTT COLOURIMETRIC ASSAY
The MTT colourimetric assay showed that alendronate stimulated cellular proliferation compared with the negative control ( Fig. 1) .
In the alendronate-treated groups, cell number was significantly greater than in the negative control group after 48 and 72 h in culture (P < 0.05); the increase was greatest (24% above the negative control value) at a concentration of 10 −8 M after 72 h. After 96 h, the rate of proliferation in alendronatetreated groups and the positive control group had decreased, and there was no significant difference in cell number between the alendronate-treated groups and the negative control group. Results with the positive control (dexamethasone) followed a similar pattern as those for the alendronate-treated groups.
ALKALINE PHOSPHATASE ASSAY
Alkaline phosphatase activity in the alendronate-treated groups was slightly lower than in the positive control (dexamethasone) and negative control (medium only) groups after 48 h of culture, but subsequently increased above the 
RT-PCR ANALYSIS
The RT-PCR analysis, performed to assess the osteogenic differentiation of MG-63 cells at the mRNA gene expression level showed that, after exposure to alendronate, expression of genes coding for BMP-2, osteocalcin and collagen I was up-regulated after 96 h of culture (Fig. 2) , expression levels being highest with 10 −8 M alendronate. The BMP2, BGLAP (osteocalcin) and COL1 (type 1 collagen) genes continued to be expressed after 7 days in culture (data not shown).
ALIZARIN RED S STAINING
As shown in 
Discussion
Bisphosphonates are usually thought to act selectively on osteoclasts in areas of high bone turnover, resulting in an antiresorptive effect. 24 Recent evidence, however, suggests that bisphosphonates may not only affect osteoclasts. Osteoblasts may also be exposed to bisphosphonate concentrations similar to those to which osteoclasts are exposed, so bisphosphonates may also have some effect on osteoblasts. Giuliani et al. 25 reported that bisphosphonates stimulated the formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures. Itoh et al. 16 suggested that clodronate stimulated osteoblast differentiation in ST2 cells (a pluripotent mesenchymal line) and MC3T3-E1 cells (an osteoblast-like cell line).
Our study shows that alendronate enhances proliferation and promotes osteogenic differentiation of cells of the MG-63 osteoblast-like cell line in a concentration-dependent manner. Alendronate increased alkaline phosphatase activity, up-regulated the expression of genes for BMP2, type I collagen and osteocalcin, and stimulated calcium deposition. These data demonstrate that alendronate, in addition to inhibiting osteoclastic bone resorption, may induce osteoblast proliferation and maturation. Cell proliferation was assessed in the present study by the MTT assay. We found that alendronate significantly increased cell number after 48 and 72 h of treatment, giving a maximum increase over the negative control of 24% at an alendronate concentration of 10 −8 M. Our data are supported by those of Itoh et al. 16 and Giuliani et al. 25 Im et al. 26 reported that alendronate increased primary human trabecular bone cell and MG-63 cell proliferation over a concentration range from 10 −5 to 10 −11 M. They also found that proliferation of these cells was inhibited at 10 −4 M alendronate, which they considered may have been due to cytotoxicity of alendronate at high concentrations.
Reinholz et al. 20 investigated the effects of pamidronate and zoledronate on human fetal osteoblast cells and found an inhibitory effect with increasing drug concentrations, but the drug concentrations they used were higher than in other studies. D'Aoust et al. 18 17 reported that alendronate at in vitro concentrations between 10 −5 and 10 −12 M had no effect on the proliferative capacity of normal human osteoblasts. The reasons for these opposing effects are unknown, but may be related to differences in cell type, the duration of treatment, the bisphosphonate analogue used and the concentrations of bisphosphonates used.
Alendronate concentration
In our experiments, alendronate increased alkaline phosphatase activity and upregulated the expression of genes for BMP2, type I collagen and osteocalcin. Alkaline phosphatase is one of the marker enzymes of mature osteoblasts and a specific index for the evaluation of osteogenic activity and tissue differentiation. The level of alkaline phosphatase activity is positively correlated with osteogenic differentiation. 26 The genes for BMP2, type I collagen and osteocalcin are osteoblast-related genes and are involved in the formation, metabolism and regeneration of bone. 27 The increased alkaline phosphatase activity and up-regulation of the genes for BMP2, type I collagen and osteocalcin are indications that alendronate treatment enhances the differentiation of MG-63 cells from the proliferation stage of development to the non-proliferating matrix maturation stage. In addition, alendronate induced deposition of mineralized matrix on the culture vessels thus indicating that alendronate further augments the development of cultured MG-63 cells from the matrix maturation stage to the mineralization stage. 20 Taken together, these results strongly suggest that alendronate induces the differentiation of MG-63 cells into more mature bone-forming cells.
Our results are basically in agreement with those of Reinholz et al. 20 and Im et al. 26 However, Itoh et al. 16 found that, although clodronate increased alkaline phosphatase activity in cultured MC3T3-E1 and ST2 cells, other bisphosphonates (pamidronate, alendronate and incadronate) did not increase alkaline phosphatase activity in either cell line. The reasons for this discrepancy are unclear, but different cell lines and culture conditions may be important factors.
Despite the discoveries discussed above, the principal mechanism for bisphosphonate-induced increases in bone mass remains unknown. In particular, the possible effects of these agents on the proliferation and differentiation of osteogenic cell populations are poorly understood. Mathov et al. 28 considered that extracellular signal-regulated kinases were involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. Fujita et al. 29 reported that bisphosphonates accelerate the mineralization of phosphatesensitized MC4 cells through the non-RAS-MEK-ERK1/2-Cbfa1 transactivation pathway. Reinholz et al. 30 showed that zoledronate induced human osteoblast differentiation by inhibition of the mevalonate pathway. Itoh et al. 16 suggested that clodronate stimulates osteoblast differentiation by inhibition of protein tyrosine phosphatase and/or serine/threonine phosphatase activity. It is possible that the mechanisms mentioned above are all involved in bone formation, although the exact mechanism of the effect of bisphosphonates on osteogenic differentiation remains unclear.
In our study we used MG-63 cells as an experimental model. These are immature osteoblast-like cells that have the potential for osteogenic differentiation. MG-63 cells are also osteogenic sarcoma cells and, because of the fast growth and infinite • Received for publication 20 October 2008 • Accepted subject to revision 24 October 2008
• Revised accepted 11 February 2009 Copyright © 2009 Field House Publishing LLP proliferation of this cell lineage, it is easy to obtain large numbers of cells. We used the MG-63 cell line in order to generate standardized, quantifiable data that would be sensitive to minor differences in drug concentrations. However, MG-63 cells have some shortcomings. For example, they have major chromosomal translocations and deletions compared with normal human osteoblasts, and the in vivo effects of bisphosphonates are more closely reflected by the human trabecular bone culture model 27 and human fetal osteoblast cells. 20 The conclusions of the present study, however, are that alendronate, at concentrations ranging from 10 −6 to 10 −10 M increases cell proliferation and alkaline phosphatase activity, up-regulates expression of the genes encoding BMP2, type I collagen and osteocalcin, and stimulates mineralization in the MG-63 osteoblast-like cell line. These results support the hypothesis that bisphosphonates have anabolic effects on osteoblasts. Although further animal and clinical experiments are needed to confirm these conclusions, bisphosphonates offer the prospect of a fascinating and promising means for the treatment of skeletal disorders.
